Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox.
It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health;U. S.
Department of Defense; and the Burnet Institute.
GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 30, 25 | -0.31 Increased by +65.93% | -0.27 Decreased by -16.98% |
| Jul 28, 25 | -0.35 Increased by +82.41% | -0.30 Decreased by -16.67% |
| May 12, 25 | -0.45 Increased by +81.78% | -0.66 Increased by +31.56% |
| Feb 26, 25 | -0.30 Increased by +97.79% | -0.77 Increased by +60.94% |
| Nov 6, 24 | -0.91 Decreased by -184.38% | -1.48 Increased by +38.51% |
| Aug 6, 24 | -1.99 Decreased by -804.55% | -3.36 Increased by +40.77% |
| May 14, 24 | -2.47 Decreased by -1.55 K% | -5.56 Increased by +55.58% |
| Feb 29, 24 | -13.60 Decreased by -6.70 K% | -2.78 Decreased by -389.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by -100.00% | -6.32 M Decreased by -8.66% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 852.28 K Increased by +183.45% | -5.37 M Decreased by -6.04% | Decreased by -630.05% Increased by +62.59% |
| Mar 31, 25 | 1.64 M Increased by +N/A% | -5.36 M Increased by +8.42% | Decreased by -327.31% Decreased by N/A% |
| Dec 31, 24 | 864.41 K Increased by +731.87% | -8.26 M Decreased by -8.83% | Decreased by -955.87% Increased by +86.92% |
| Sep 30, 24 | 2.79 M Increased by +N/A% | -5.82 M Increased by +30.84% | Decreased by -208.48% Decreased by N/A% |
| Jun 30, 24 | 300.68 K Increased by +N/A% | -5.06 M Increased by +14.57% | Decreased by -1.68 K% Decreased by N/A% |
| Mar 31, 24 | 0.00 Increased by +100.00% | -5.85 M Decreased by -44.88% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 103.91 K Increased by +227.46% | -7.59 M Decreased by -41.15% | Decreased by -7.31 K% Decreased by -210.75% |